This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert D. Gibbons, PhD; John M. Davis, MD; Donald R. Hedeker, PhD
Biometric Laboratory Illinois State Psychiatric Institute 1601 W Taylor St Chicago, IL 60612

Arch Gen Psychiatry. 1990;47(8):785-786.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In a recent meeting on the design and analysis of multicenter clinical trials in psychiatric research sponsored by the MacArthur Foundation, Stanford, Calif, we were asked to present some statistical comments. Our first concern was the magnitude of center effects and potential center x diagnosis or center x treatment interactions. To obtain some insight into this problem we examined much of the world's data on cerebrospinal fluid biogenic amines (5-hydroxyindoleacetic acid [5-HIAA], homovanillic acid [HVA], and 3-methoxy-4-hydroxyphenylglycol). These data, for which summary statistics are presented in Table 1, came from the National Institute of Mental Health (NIMH) (Bethesda, Md) Intramural Study Center (access provided by William Potter, MD), the NIMH Biological Collaborative Study (Koslow et al,¹ 1983), The Nancy Pritzker Laboratory at Stanford (Calif) University (J. D. Barchas, MD, and K. F. Faull, PhD), the Karolinska Institute in Stockholm, Sweden (Marie Asberg, MD), the University of Uppsala, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?